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SUMMARY 
The role of antibody and cell-mediated immunity in the resistance to Japanese 
encephalitis virus (JEV) infection was studied in adult mice. Passively transferred 
antibodies obtained up to 2 weeks after primary infection protected the recipient mice 
against a challenge infection with JEV. Antibody obtained at 4 or 5 weeks failed to 
protect despite the presence of high titres of neutralizing antibody. Protection was 
abrogated by pretreatment of he early serum with 2-mercaptoethanol to remove ]gM. 
Similarly, adoptive transfer of immune spleen cells obtained up to 2 weeks after 
immunization provided protection. The protective ffect was abolished by pretreat- 
ment of the immune spleen cells with anti-Thy 1.2 antiserum and complement. These 
findings suggest a role of T lymphocytes and IgM antibody in recovery from JEV 
infection. 
INTRODUCTION 
Host defence against viral infection is mediated by a complex mechanism involving various 
humoral and cellular effector mechanisms which may act alone (Zisman et al., 1971 ;Camenga et 
al., 1974; Chaturvedi et al., 1977, 1978; Rager-Zisman & Allison, 1973; Blanden, 1971) or 
usually in cooperation (Rabinowitz & Adler, 1973; McFarland et al., 1972). 
The outbreak of a wide-spread epidemic of Japanese ncephalitis n Uttar Pradesh, India 
during 1978 (Mathur et aL, 1982a; Chaturvedi et aL, 1980) aroused our interest in this problem. 
The role of the immune response in recovery from infection with Japanese ncephalitis virus 
(JEV) is poorly understood. Haemagglutination-inhibiting (HAI) antibody has been suggested 
to play a protective role against JEV in mice (Grossberg & Scherer, 1966) and neutralizing 
antibody in gibbons (Edelman et al., 1973). Mori et al. (1970) have shown that thymus-deprived 
mice have an impaired anti-JEV antibody response. However, our recent studies how that HAI 
antibodies do not appear to be the major determinant ofrecovery after primary JEV infection in 
mice, nor do they prevent subsequent infection. HAI antibodies were produced after primary 
infection of pregnant mice but JEV nevertheless persisted and was transmitted transplacentally 
in consecutive pregnancies (Mathur et al., 1982b). 
The present study was undertaken to investigate the humoral and cell-mediated immune 
(CMI) responses in mice and their role in recovery from infection. 
METHODS 
Virus. JEV strain 78668A was used in the form of an infected adult mouse brain suspension asdescribed 
previously (Mathur et al., 1981, 1982a). It produced 100~ mortality by day 6 following intracerebral (i.c.) 
inoculation, while no mortality was seen after infection using the intraperitoneal (i.p.) route. 
Infection of mice. Inbred Swiss albino mice 4 to 6 months oldwere infected by inoculating 0.5 ml ofa 20~ JEV- 
infected mouse brain suspension i.p. In the brain virus assay experiment, mice were also in culated i.c. 
Preparation of spleen cells. Mice were inoculated either i.c. or i.p. with 102 LDso of JEV and were killed in 
batches of three or four daily up to day 21. The spleen cells were teased out in chilled Eagle's minimum essential 
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medium containing 10~o foetal calf serum (Armour Pharmaceutical, Sussex, U.K.) and a single cell suspension 
was prepared. The final suspension contained 90 to 95 ~ viable nucleated cells as assessed by tr pan blue staining. 
Leukocyte migration inhibition (LMI) test. The LMI test was done on spleen cells using the technique of David et 
al. (1964) as described in detail by Chaturvedi et al. (1978). The tests for each mouse were done in triplicate. The 
migration pattern of leukocytes was recorded after incubation for 24 h at 37 °C. The percentage migration 
inhibition was calculated from the area of cell migration in the presence of JEV antigen compared with normal 
mouse brain suspension, and an inhibition of 20~ or more was considered significant. 
Antibody plaqueqorming cells (PFC). A spleen cell suspension was prepared and cells forming antibody against 
JEV were counted by localized haemolysis n gel as described in detail elsewhere (Chaturvedi eta/., 1977). Only 
direct PFC were counted. Multiple slides were prepared for each mouse. Mean values with standard eviations 
have been calculated after deducting background PFC. 
Antibody titre. The HAI test was performed by the technique of Clarke & Casals (1958) using the microtitre 
technique as described previously (Mathur et al., 1982 a). The sera were treated with kaolin and heat inactivated at 
56 °C for 30 min. Freeze-dried JEV antigen (P20778) was provided by The National Institute of Virology, Pune, 
India. JEV-specific IgM HAI antibody was detected by fractionation of serum on a sucrose density gradient, with 
or without treatment of the fractions with 2-mercaptoethanol (2-ME) as described previously (Mathur et al., 
1982a). 
Neutralization test. Sera were inactivated at 56 °C for 30 min and neutralization tests carried out in fant mice 
as described previously (Mathur et al., 1982a). 
Depletion ofT and B cells. The spleen cell suspension was treated with anti-Thy 1.2 antibodies (New England 
Nuclear) at 4 °C for 1 h, after which fresh guinea-pig serum (1:6 dilution) was added. After incubation at 37 °C for 
1 h, the viable cells were counted by dye exclusion (Golub, 1971). After this treatment 41 ~ of the spleen cells 
became non-viable. To deplete B cells the spleen cell suspension was treated with anti-mouse IgG serum and 
complement as described above. 
Adoptive immunization by spleen cells. Immune spleen cells obtained at different periods after immunization were 
injected intravenously (i.v; 1 x 10 s cells) into recipient mice, which were challenged 24 h later by inoculation of 
10-' LDs0 JEV i.c. Mice of control groups received spleen cells from non-immune donors. 
Passive immunization by serum. Blood was collected from immunized onor mice at weekly intervals up to 5 
weeks after the last dose of J EV. The sera diluted 1:10 or 1:100 were injected in doses of 0.5 ml i.p. into groups of 
normal mice followed 24 h later by 10 e LDs0 of JEV i.c. Animals of control groups received serum from non- 
immune mice. 
2-ME treatment qfsera beJbrepassive immunization. To study the role of IgM antibody in protection against JEV 
challenge, the sera obtained at 1 to 5 weeks after immunization were treated with 2-ME and were then dialysed to 
remove 2-ME as described by Svehag & Mandal (1964). Mice of one group were given the 2-ME-treated immune 
sera i.v., others were given untreated immune sera and the control group received serum from normal mice. Mice 
were challenged with 102 LDs0 JEV i.c. 24 h later and were observed for mortality. 
RESULTS 
Development of  the cell-mediated immune response 
The LMI  has been taken as an index of the cel l -mediated immune response produced after  
JEV  infection. The results summar ized  in Fig. 1 show a s ignif icant migrat ion  inh ib i t ion  in the 
presence of specific ant igen from day 3 to day 18 of  the study. The  response was s imi lar  by e i ther  
route of  virus inoculat ion.  
Development of  antibody plaque-forming cells 
To study the immune response of mice to JEV  dur ing the early phase  of  in fect ion ant ibody  
PFC were counted in spleen suspensions.  When the virus was g iven i.p. the PFC count  increased 
f rom 284/2 x 106 spleen cells on day 1 to a peak of  640/2 x 106 spleen cells on day 6 and  then  
decl ined to 355/2 × 106 spleen cells on day 9. The  PFC counts  were s imi lar  in mice g iven virus 
i.c. (Fig. 2). 
Production of  neutralizing and HAI  antibodies after immunization 
Table 1 demonst rates  the HAI  and  neutra l iz ing ant ibody  response est imated in mice at 
dif ferent weeks fol lowing i.p. inoculat ion of  JEV.  H igh t itres of  JEV  HAI  and  neutra l i z ing  
ant ibody  were found in serum by week 5 post- infect ion.  JEV-speci f ic  IgM HAI  ant ibody  (2- 
ME-sens i t ive)  was present  in serum 1 and  2 weeks after  infect ion. The  presence of  JEV-speci f ic  
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Fig. 1. Leukocyte migration inhibition of spleen cells ofmice on different days after intraperitoneal 
(0) or intracerebral (A) inoculation of JEV. Each observation represents the mean value with its 
standard error from multiple readings from five mice. 
Fig. 2. Antibody plaque-forming cells in the spleen of mice on different days after intraperitoneal (0) 
or intracerebral (A) inoculation ofJEV. Each observation represents the mean value with its standard 
error from multiple slides from five mice. 
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Table 1. Antibody response in mice at different periods after i.p. inoculation of JEV* 
Time of HA1 antibody titre Neutralizing 
post-immunization , x ~ antibody 
(weeks) Controlt 2-ME~ titre 
1 16 <8 8 
2 64 8 32 
3 128 64 64 
4 128 64 128 
5 128 128 256 
* Mice were given a 20~ JEV-infected mouse brain suspension i.p. Haemagglutinating and neutralizing 
antibodies were measured at different weeks after virus infection. 
t Serum aliquot treated with buffer. 
$ Serum aliquot treated with 2-mercaptoethanol. 
IgM was confirmed by screening fractions obtained from sucrose density gradient 
centrifugation of serum (Table 2). 
Assay of virus in brain 
The titres of JEV in the brain of mice after i.p. or i.c. inoculation of the virus are presented in 
Fig. 3. The virus titre gradually increased in mice given virus i.c. but no virus was isolated from 
the brain of i.p. inoculated mice. 
Transfer of resistance by spleen cells 
Immune spleen cells obtained from donor mice at 1 and 2 weeks after primary infection were 
capable of conferring protection to recipient mice against i.c. challenge with JEV (Fig. 4). 
Spleen cells harvested at 3 to 5 weeks failed to protect he mice. Transfer of normal mouse spleen 
cells had no antiviral activity. The relationship between the number of transferred immune 
spleen cells and protection was studied. It was observed that there was little or no protection 
when less then 108 cells were transferred (Table 3). 
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Fig. 3. Virus titres in brain on various days after intraperitoneal (0)  or intracerebral (A) inoculation 
of JEV. Each point represents he mean value from five mice. 
Fig. 4. Effect of adoptive transfer of immune spleen cells on JEV infection. Spleen cells obtained at I to 
5 weeks after immunization with JEV were injected intravenously with doses of 108 cells followed 24 h 
later with 102 LD50 of JEV intracerebrally. II, Mice given immune spleen cells; IS], mice given normal 
spleen cells. 
Table 2. JEV-specific IgM antibodies in serum fractions of mice* 
Time HA1 antibody titre 
after immunization Serum c A 
(weeks) fraction Contro D 2-ME 
1 3 4 0 
4 4 0 
5 8 0 
2 3 8 0 
4 8 0 
5 16 0 
3 3 8 4 
4 16 8 
5 32 32 
4 3 16 8 
4 16 16 
5 32 32 
5 3 16 16 
4 16 16 
5 32 32 
* Mice were given a single i.p. injection of JEV. Blood was collected at weekly intervals. Presence of IgM 
antibodies in serum fractions obtained by sucrose density gradient centrifugation was detected by radial 
immunodiffusion (Mancini et al., 1965). IgM was found in serum fractions 3, 4 and 5 ; therefore, in these fractions 
HAl antibodies were measured before and after treatment with 2-ME. 
l" Serum sucrose fraction treated with buffer. 
Effect of depletion of T and B lymphocytes on the transfer of resistance by immune spleen cells. 
Immune spleen cell suspensions were treated with anti-Thy 1.2 ant ibody and complement  or 
with anti-mouse globulin and complement.  108 cells, either treated or untreated, were injected 
i.v. into recipient mice, followed by i.c. challenge with JEV. The findings summarized in Table 4 
show that the protective ffect of the adoptively transferred immune spleen cells is abrogated by 
depletion of  T lymphocytes with anti -Thy 1.2 antibody. Protect ion was not affected by 
deplet ion of B lymphocytes with anti-mouse globulin (Table 4). 
Transfer of resistance by antisera 
The data presented in Table 5 show that sera obtained at 1 and 2 weeks after pr imary infection 
protected the recipients against i.c. chal lenge with JEV.  Sera obtained at 3 weeks after infection 
provided only slight protection and those from later bleeding none at all. 
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Table  3. Relationship between number of immune spleen cells transferred an  protection* 
No. of spleen cells Death/total Mortality (%) 
Immune 200 x 106 1/20 5 
100 x 106 1/20 5 
10 × 106 18/20 90 
106 19/20 95 
Normal 200 × 106 20/20 100 
* Immune spleen cells were obtained 7days after immunization with JEV. Mice receiving i.v. transfers of cells 
were challenged 24 h later with 102 LDs0 of JEV i.e. 
Treatment of 
immune spleen 
cells 
Immune 
ATSt 
AOS~ 
Untreated 
Normal 
Without cells 
Table  4. Antiviral activity of immune spleen cells treated with various antisera 
Time after primary infection (weeks)* 
A 
1 2 3 4 5 
~k A. ,A ~k ak 
r • r ~ g • og ~ ¢ 
% M MDD % M MDD % M MDD % M MDD % M MDD 
95 6 95 6-2 100 6-1 100 6.1 100 6.2 
10 11-0 10 11-5 85 8-0 100 7.0 100 6.5 
10 11.4 5 12.0 85 8.3 95 7.4 100 6.5 
95 6-5 100 6-0 100 6.1 100 6.2 95 6.0 
100 6.0 100 6.0 100 6.2 100 6.0 100 6.0 
* Immune spleen cells were obtained at weekly intervals after a single i.p. dose of 0.5 ml of a 20% JEV-infected 
mouse brain suspension. 108 untreated or pretreated immune spleen cells were injected i,v. into recipient mice 
which were challenged 24 h later with 102 LDso of JEV i.e. % M, Percentage mortality; MDD, median day of 
death. 
t Immune spleen cells treated with anti-Thy 1,2 antiserum and complement. 
2~ Immune spleen cells treated with anti-mouse globulin antiserum and complement. 
Serum 
dilution 
Immune 
1:10 
1:100 
Normal 
1:10 
Without serum 
0 
Tab le  5. Antiviral activity of immune mouse sera 
Time after primary infection (weeks)* 
A t 
1 2 3 4 5 
' b ' ' ' 6 ' ; ' % M MD % M MDD % M MD % M MD % M MDD 
10 12-0 0 0 75 11.4 100 6.5 100 6.0 
20 12-1 5 12-0 85 10-3 100 6.2 100 6.0 
100 6.2 100 6.0 95 6-0 95 6.0 100 6.0 
100 6.0 100 6.1 100 6.7 100 6.3 100 6.2 
* Mice were immunized by a single i.p. injection of JEV. Blood was collected at weekly intervals and 0.5 ml 
serum dilutions were injected i.v. into normal mice which were challenged 24 h later with 102 LDs0 of JEV i.e. A 
control group was given normal mouse serum. Each group consisted of 20 mice. % M, Percentage mortality; 
MDD, median day of death. 
Passive immunization using 2-ME-treated antisera 
The purpose of  this exper iment  was to determine  the role of  IgM ant ibod ies  in conferr ing 
protect ion.  Immune sera at dif ferent weeks after  p r imary  infect ion were t reated w i th  2 -ME to 
remove IgM ant ibodies.  The  morta l i ty  was h igher  in mice g iven 2 -ME- t reated  ant i sera  than  in 
an imals  which had received untreated immune sera (Table 6). The  di f ference between untreated 
and  2-ME-t reated serum obta ined at week 1 and  week 2 after  immunizat ion  was highly 
s ignif icant (P  < 0.001). 
DISCUSSION 
In the present  study the immune response and the protect ive effect of pass ive adopt ive  
immunizat ion  were invest igated.  The leukocyte migrat ion  inh ib i t ion  test showed a short - l ived 
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Table 6. Failure of  2-mercaptoethanol-treated immune sera to protect against i.c. challenge with 
JEV* 
Untreated 
Time a f te r  2-ME-treated immune serum Normal serum 
primary immune serum ( 1 : 10) ( 1 : 10) 
~nfection • ~ r ~ ~ , x 
(weeks) % M MDD" ~ M MDD ~ M MDD 
1 90 9.0 20 11.5 100 6 
2 95 10-0 15 10-2 95 6 
3 95 8-2 85 6-5 95 6 
4 100 6-0 100 6.0 100 6 
5 100 6.0 100 6-0 100 6 
* Mice were given 0.5 ml pretreated or untreated sera i.v. and were challenged 24 h later with 10 ~ LDso of JEV 
i.c. Each group consisted of20 mice. ~o M, Percentage mortality; MDD, median d yof death. 
CMI lasting up to 2 weeks after priming. Transient CMI has been shown in a number of studies, 
namely influenza (Hellman et al., 1972), Sindbis and VEE (Rabinowitz & Adler, 1973) virus 
infections. The mechanism of such a transient response is not well understood. On the other 
hand, the humoral immune response to JEV appeared prolonged. The PFC response appeared 
as the usual 'bell-shaped' curve with peak counts on the 6th day, whereas the HAI and the 
neutralizing antibodies w re first detectable at 1 week and persisted for 5 weeks after infection. 
The CMI and the humoral immune responses were similar irrespective of whether the virus was 
given by the i.p. or the i.c. route. Virus given i.c. replicated in the brain reaching high titres while 
it failed to enter the brain when given by the i.p. route (Fig. 3). Involvement ofthe brain appears 
essential to bring about morbidity and mortality in JEV infection. 
Adoptive transfer of immune spleen cells had a protective ffect against JEV challenge. The 
protection was abrogated by pretreatment of the immune spleen cells with anti-Thy 1.2 
antiserum and complement; pretreatment with anti-globulin antiserum and complement had no 
effect. This implies that the protection ismediated by T lymphocytes. The immune spleens cells 
were effective only up to 2 weeks after priming; ceils taken at later periods after immunization 
failed to provide protection. This correlates with the transient presence of CMI as shown by the 
LMI test. Passive transfer of immune serum obtained up to2 weeks after priming also provided 
protection against JEV. The protective ffect was abolished by pretreatment of the immune sera 
with 2-ME. This suggests that the protection against JEV was provided by IgM antibodies; 
purified specific IgM is required to further confirm this conclusion. Serum obtained after 4 weeks 
of immunization had high HAI antibody titres but failed to provide protection. 
The role of antibodies in protection against JEV infection is not clear. Fatal encephalitis 
seen in horses and pigs in the presence of neutralizing and complement-fixing antibodies 
(Rhodes & van Rooyen, 1968; Ueba et al., 1972). The co-existence of JEV with its HA1 
antibodies i seen in blood of vaccinated pigs (Ueba et al., 1972). We have observed earlier that 
JEV is transmitted to the foetus even when the mother had JEV HAI and neutralizing 
antibodies (Mathur et al., 1982b). The HAl and neutralizing antibodies against JEV in man are 
both IgM and IgG in nature (Ishii et al., 1968). The findings of the present study indicate hat 
IgM antibodies are protective in JEV infection of mice. This observation is supported by the 
clinical studies of Edelman et al. (1976) who reported isappearance of the neurological signs in 
patients of Japanese ncephalitis n the presence of IgM antibodies. 
The half-life of IgM antibodies in mice is less than 4 days (Mims, 1983) and the above transfer 
experiments show that immune cells are effective for 2 weeks only. If JEV escapes immune 
surveillance during this period, a persistent infection may result. Our earlier studies have shown 
that when JEV is inoculated i.p. into pregnant mice, infectious virus can be demonstrated in 
body tissues up to 17 weeks after infection. We were unable to isolate JEV from these animals 
later; during a subsequent pregnancy, however, virus transmission to the foetus was noted 
(Mathur et al., 1982b). Pregnancy isknown to depress the immune response (Ceppellini, 1971). 
The above experiments show that in the absence of IgM antibodies JEV is not eliminated. 
Boosting and sustaining the production of IgM antibodies against the virus may be considered as 
the main host defence mechanism. 
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